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Background: Identification of specific mutations in cancer patients may lead to the discovery of genes, which can
affect susceptibility and/or prognosis. It has previously been reported that mutations in BRCA1 and BRCA2 genes are
linked to breast cancer. Here, we evaluated the use of the High Resolution Melting (HRM) approach to screen for
mutations in exon 11 of BRCA1 gene in Moroccan patients.
Methods: HRM analysis was used to screen exon 11 from 71 breast cancer patients in order to detect different
variants. Conventional Sanger sequencing was used to confirm the presence of possible mutations. Distribution of
different SNPs was determined by SNaPshot analysis software.
Results: In order to assess the efficacy of the HRM approach to screen for mutations, especially in diagnosis, we
first used two samples with previously known mutations, “2924delA and 3398delC”. Indeed, these previously known
sequence variants were detected by the HRM approach and yielded melting curves with atypical shape relative to
wild-type control sequences. We then analyzed, 69 samples from breast cancer patients using the HRM method,
and were able to detect two samples with atypical curves. Sequencing of the two samples, using the conventional
Sanger approach, confirmed the presence of the same SNP (c.2612C > T) in both samples.
Conclusions: Our results strongly suggest that the HRM approach represents a reliable and highly sensitive method
for mutation scanning, especially in diagnosis.
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BRCA1 is a tumor suppressor gene located on chromo-
some 17, position 17q21 in humans. It is comprised of
24 exons spread over 81 kb of DNA, 22 of which are
coding exons. These exons encode a transcript of about
7000 bp translated into a protein of 1863 amino acids [1].
Exon 11 of BRCA1 is a large central exon of 3426 bp. This
exon represents 60% of the coding sequence.
Nowadays, it is common knowledge that germ-line
mutations of the BRCA1 gene are high risk factors for
developing breast cancer [2]. Since the identification of
this particular gene two decades ago [3], it is now* Correspondence: el.khachibi.meryam@gmail.com
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breast and ovarian hereditary predisposition syndrome [4].
Although Sanger sequencing remains the most reliable
technique to identify sequence variants, this approach is
costly and time consuming. In order to establish an
accurate prognosis in breast cancer patients through the
identification of BRCA1 sequence variants, a number of
specific screening procedures, which are both cost- and
time- effective have been developed [1].
In Morocco, conventional sequencing techniques have
been used to sequence BRCA1 [5,6]. However, sequencing
is quite expensive and since Morocco is a low-income coun-
try, most of its patients can’t afford this type of check-up.
The HRM method is a scanning technique that enables
mutation scanning and amplification to be performed
readily, and in one step [2]. This is a method in which onlytral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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no sample processing (after PCR amplification) is required
[7]. It is important to note that the HRM technique also
allows heteroduplex detection.
Several studies have been conducted to scan BRCA1
exons by the HRM approach [2,8-11]. However, to our
knowledge, this is the first study performed in Morocco
using the HRM approach to screen the BRCA1 gene.
Our aim was to explore the reliability of the HRM
approach for the identification of BRCA1 mutation carriers
in exon 11 among family members of an index patient (IP);
and to search for the presence of new genetic variants in
the Moroccan population. In the first part of this study,
we analyzed and detected, using the HRM approach,
variants from samples of patients presenting with breast
cancer. In the second part, we corroborated the results




We started our work with two previously sequenced,
positive controls (2924delA and 3398delC). 71 patients,Table 1 List of primers used to amplify the BRCA1 gene exon
Gene
BRCA1 Forward primer
exon 11 A Reverse primer
BRCA1 Forward primer
exon 11 B Reverse primer
BRCA1 Forward primer
exon 11 C Reverse primer
BRCA1 Forward primer
exon 11 D Reverse primer
BRCA1 Forward primer
exon 11 E Reverse primer
BRCA1 Forward primer
exon 11 F Reverse primer
BRCA1 Forward primer
exon 11 G Reverse primer
BRCA1 Forward primer
exon 11 H Reverse primer
BRCA1 Forward primer
exon 11 I Reverse primer
BRCA1 Forward primer
exon 11 J Reverse primer
BRCA1 Forward primer
exon 11 K Reverse primer
BRCA Forward primer
exon 11 L Reverse primerfound positive for breast cancer through clinical and
histological examinations, were recruited from private
and public oncology centers of Casablanca from 2009 to
2010. Five more donors were used as negative healthy
controls.
Experiments performed in this study were evaluated
and approved by the Ethic Committee for Biomedical
Research in Casablanca (CERBC) of the Faculty of Medi-
cine and Pharmacy (N° 121). For this purpose, a written
consent (including the agreement to publish clinical data)
was given by each study participant (patient and control).
DNA was extracted using the phenol-chloroform method
as previously described, [12] and quantified using the
NanoVue™ Plus Spectrophotometer (GE Healthcare, UK).
HRM protocol
Assays were performed in 96 well plates. Amplification
by PCR, of exon 11 of BRCA1 was performed using
primers reported by P. D. Murphy in 2005 (see Table 1)
[13] using a 7500 Fast Real-Time PCR system (AB Ap-
plied Biosystems, USA). Analysis of the obtained curves
was performed using the 7500 Fast System SDS v2.0.1
software.11
Sequence Taille
5’ CCACCTCCAAGGTGTATCA-3’ 372 bp
5’ TGTTATGTTGGCTCCTTGCT-3’
5’ CACTAAAGACAGAATGAATCTA-3’ 400 bp
5’ GAAGAAGCAGAATATTCATCTA-3’
5’ TGATGGGGAGTCTGAATCAA-3’ 400 bp
5’ TCTGCTTTCTTGATAAAATCCT-3’
5’ AGCGTCCCCTCACAAATAAA-3’ 400 bp
5’ TCAAGCGCATGAATATGCCT-3’
5’ GTATAAGCAATATGGAACTCGA-3’ 388 bp
5’ TTAAGTTCACTGGTATTTGAACA-3’
5’ GACAGCGATACTTTCCCAGA-3’ 382 bp
5’ TGGAACAACCATGAATTAGTC-3’
5’ GGAAGTTAGCACTCTAGGGA-3’ 423 bp
5’ GCAGTGATATTAACTGTCTGTA-3
5’ TGGGTCCTTAAAGAAACAAAGT-3’ 366 bp
5’ TCAGGTGACATTGAATCTTCC-3’
5’ CCACTTTTTCCCATCAAGTCA-3’ 377 bp
5’ TCAGGATGCTTACAATTACTTC-3’
5’ CAAAATTGAATGCTATGCTTAGA-3’ 377 bp
5’ TCGGTAACCCTGAGCCAAAT-3’
5’ GCAAAAGCGTCCAGAAAGGA-3’ 396 bp
5’ TATTTGCAGTCAAGTCTTCCAA-3’
5’ GTAATATTGGCAAAGGCATCT-3’ 360 bp
5’ TAAAATGTGCTCCCCAAAAGCA-3’
Figure 1 Aligned melt curves of 71 patients.
El Khachibi et al. BMC Cancer  (2015) 15:81 Page 3 of 5In these experiments, we used MeltDoctor ™ HRM
Master Mix kit reagents, which contain HRM SYTO9, a
DNA intercalating fluorescent agent (BIOLINE, LONDON,
UK). The final volume in the reaction mixture is 20 μl
(4.4 μl of water, 10 μl of Master Mix, 0.25 μl of each primer
(10 μM) and 20 ng of genomic DNA). The HRM protocol
was set as follows:
– One cycle of 95°C for 10 min;
– 40 cycles of 95°C for 10 s, 63°C for 30 s and 72°C
for 20 s;
– One cycle of melt curve of 95°C for 10 s, 60°C for
1 min, 95°C for 15 s and 60°C for 15 s. In these
experiments, we used the same Tm of 63°C for all
the primers.
DNA sequencing
To validate the HRM method, we reanalyzed all of the
samples that yielded atypical curves, using conventional
Sanger sequencing. These DNA samples were firstFigure 2 Difference plots of region H of the BRCA1 gene exon 11 betweamplified in a final volume of 25 μl containing: 5× reac-
tion buffer, 1.5 mM MgCl2, 50 μM primers (same
primers used for HRM method), 0.25 U Taq polymerase
(BIOLINE, LONDON, UK) and 50 ng of genomic DNA.
All the PCR products were treated with exonuclease
I and shrimp alkaline phosphatase enzymes prior to
sequencing according to the following protocol: 37°C
for 40 min and 80°C for 15 min. Then, the obtained
PCR products were sequenced using the forward primer,
the BigDye Terminator v 1.1Standard Kit (Applied Biosys-
tems, Foster City, CA, USA), and the sequencher 3100
ABI Applied Biosystems. With regard to the analysis, we
used the Applied Biosystems SeqScape Software v2.5
SNaPshot analysis.
Results
The first step of this work was to validate the HRM
approach for the entire sequence of the Exon 11 of
BRCA1 gene. In order to accomplish this, we used DNA
samples from five healthy control donors to amplify allen wild-type and c.3279delC and 2805delA mutations (a and b).
Figure 3 Difference plots of region G of the BRCA1 gene exon 11 between wild-type and c.2612C > T SNP (a; b), Electropherograms
showing sequencing results for c.2612C > T SNP (c).
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DNA samples, in which mutations had previously been
detected within the region H of exon 11 (see Table 1) [5].
As expected, all sequence variants in which mutations
were previously detected yielded melting curves with
abnormal shapes relative to wild-type DNA. In order to
corroborate our observation, we sequenced the two
samples that exhibited atypical curves, and found that
these samples possessed a SNP. Indeed, The B, C, D, E, F,
I, K and L regions of exon 11 (see Table 1) did not show
atypical curves (Figure 1); whereas the G and H regions
of exon 11 (see Table 1) exhibited different atypical
curves (Figures 2 and 3). All of these variants have been
sequenced except for the samples Br 23 and Br 24,
already known to carry mutations in the region H of
exon 11 (see Table 2 for details).
Our work has shown that the HRM approach is sensi-
tive, specific and straightforward. This method would
also help to avoid costly systematic sequencing. In fact,
sequencing, in this case, would be performed only for











BRCA1 Br 23 11 H Positive Positive c.2805delA 2924de
Br 24 11 H Positive Positive c.3279delC 3398de
Br 123 11 G Positive Positive _ _
Br 12 11G Positive Positive _ _
BC: Breast Cancer.Discussion
In order to detect potential mutations and, at the same
time, avoid sequencing the entire BRCA1 gene, several
alternate methods have been suggested to screen this gene.
For instance, De Leener, et al. used the Protein Truncation
Test (PTT), denaturing Gradient Gel Electrophoresis
(DGGE) and denaturing High-Performance Liquid Chro-
matography (dHLPC), followed by specific region sequen-
cing [8]. While all these methods were considered to be
relatively sensitive, these approaches, especially the PTT,
were shown to be unable to detect all of the mutations
[11]. The purpose of our study was to evaluate the efficacy
of the HRM method in screening large sequences for
potential mutations.
The High Resolution DNA Melting Analysis was first
described by Zhou et al. [14], where the authors analyzed
the ΔF508 mutation associated with the Mucoviscidosis dis-
ease. These authors also analyzed, using the same approach,
other mutations found in the factor V gene: F508C variants
in exon 10; and G551D, G542X, and R553X variants in









lA _ BC, 41y M aunt, BC 42 y Berber
lC _ BC, 32y Mother, BC 49 y Berber
c.2612C > T BC, 64y No Family History Berber
c.2612C > T BC, 27y No Family History Arab
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nique, several groups have reported, in agreement with
this work, that this method enables the detection of vari-
ants [1,2,8,10,11,15,16]. In these reports, positive controls
were also used to confirm the specificity and sensitivity of
this technique [1,2,8,10,11,15,16]. In 2009, De Juan, et al.
used the HRM method followed by sequencing to scan for
mutations in the BRCA1 and BRCA2 genes [11]. Further-
more, in 2011, the same team reported various advantages
of the HRM analysis, and confirmed that this method is
much faster than Conformation Sensitive Gel Electro-
phoresis (CSGE) screening [4]. Altogether, these reports
are in agreement with this study, and indicate that the
HRM approach is suitable as a primary screening method
of large DNA sequences, especially in diagnosis.
Conclusion
In the present study, we show that the HRM approach
allows for the screening of mutations across large DNA
sequences. DNA samples that produce plots which are
distinct from the wild-type, should be sequenced to
confirm and identify the specific mutations, or SNPs.
Finally, we demonstrate that the HRM approach, which
is very sensitive, specific, cost-effective, and fast, can be
used efficiently, especially in diagnosis.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ME carried out the molecular genetic studies, took part in gathering the
patients’ recruitment and drafted the manuscript. BD participated in the
analysis of the HRM curve. KH and AB revised the manuscript. MAS helped
analyze the sequencing result. AB assisted in the sequencing experiment. HJ
and AB coordinated the patient’s recruitment and provided the clinical data.
AB supervised the sequencing experiment. SN conceived the study and
participated in its design and coordination. All authors read and approved
the final manuscript.
Acknowledgements
We gratefully acknowledge the members of LGMP and the Oncology
department. We are also indebted to Amal TAZZITE for her help with the
positive controls. This study was supported by Casablanca Hassan II
University and Casablanca Medical and Pharmacy School.
Author details
1Genetics and Molecular Pathology Laboratory, Medical school of Casablanca,
Casablanca, Morocco. 2Department of Oncology, Ibn Rochd University
Hospital, Casablanca, Morocco. 3Laboratoire de Génétique Moléculaire
Humaine, Département de la Recherche Scientifique, Institut Pasteur du
Maroc, Casablanca, Morocco.
Received: 6 May 2014 Accepted: 23 January 2015
References
1. Hondow HL, Fox SB, Mitchell G, Scott RJ, Beshay V, Wong SQ, et al. A
high-throughput protocol for mutation scanning of the BRCA1 and BRCA2
genes. BMC Cancer. 2011;11:265.
2. Takano EA, Mitchell G, Fox SB, Dobrovic A. Rapid detection of carriers with
BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC
Cancer. 2008;8:59.3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S,
et al. A strong candidate for the breast and ovarian cancer susceptibility
gene BRCA1. Science. 1994;266:66–71.
4. de Juan JI, Cardeñosa EE, Suela SP, González EB, Trejo DS, Lluch OF, et al.
Advantage of high-resolution melting curve analysis over conformation-
sensitive gel electrophoresis for mutational screening of BRCA1 and BRCA2
genes. Clin Chim Acta. 2011;412:578–82.
5. Tazzite A, Jouhadi H, Nadifi S, Aretini P, Falaschi E, Collavoli A, et al. BRCA1
and BRCA2 germline mutations in Moroccan breast/ovarian cancer families:
novel mutations and unclassified variants. Gynecol Oncol. 2012;125:687–92.
6. Tazzite A, Nadiffi S, Kottwitz D, El Amrani M, Jouhadi H, Benider A, et al.
Specific BRCA1 gene variations amongst young Moroccan breast cancer
patients. Genet Mol Res. 2014;13:791.
7. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of
DNA melting curves during the polymerase chain reaction. Anal Biochem.
1997;245:154–60.
8. De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K. Rapid and sensitive
detection of BRCA1/2 mutations in a diagnostic setting: comparison of two
high-resolution melting platforms. Clin Chem. 2008;54:982–9.
9. Dufresne SD, Belloni DR, Wells WA, Tsongalis GJ. BRCA1 and BRCA2 mutation
screening using SmartCycler II high-resolution melt curve analysis. Arch
Pathol Lab Med. 2006;130:185–7.
10. Kroupis C, Christopoulos K, Devetzoglou M, Tsiagas I, Lianidou ES.
Asymmetric real-time PCR detection of BRCA1 5382insC mutation by
melting curve analysis in the LightCycler. Clin Chim Acta. 2008;390:141–4.
11. de Juan I, Esteban E, Palanca S, Barragán E, Bolufer P. High-resolution melting
analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations. Breast
Cancer Res Treat. 2009;115:405–14.
12. Santos E, Paula J, Motta P, Heinemann M, Leite R, Haddad J, et al. Comparison
of three methods of DNA extraction from peripheral blood mononuclear cells
and lung fragments of equines. Genet Mol Res. 2009;9:1591–8.
13. Murphy PD. Method for determining the haplotype of a human BRCA1
gene. In: Book Method for determining the haplotype of a human BRCA1
gene, Google Patents. 2005.
14. Zhou L, Wang L, Palais R, Pryor R, Wittwer CT. High-resolution DNA melting
analysis for simultaneous mutation scanning and genotyping in solution.
Clin Chem. 2005;51:1770–7.
15. van der Stoep N, van Paridon CD, Janssens T, Krenkova P, Stambergova A,
Macek M, et al. Diagnostic guidelines for high‐resolution melting curve
(HRM) analysis: An interlaboratory validation of BRCA1 mutation scanning
using the 96‐well LightScanner™. Hum Mutat. 2009;30:899–909.
16. De Leeneer K, Coene I, Poppe B, De Paepe A, Claes K. Genotyping of
frequent BRCA1/2 SNPs with unlabeled probes: a supplement to HRMCA
mutation scanning, allowing the strong reduction of sequencing burden.
J Mol Diagn. 2009;11:415–9.
